| Dr Salvatore Joseph Vella Jr, DO | |
|
280 Main St, Second Floor, Nashua, NH 03060-2919 | |
| (603) 577-3300 | |
| (603) 577-3398 |
| Full Name | Dr Salvatore Joseph Vella Jr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 29 Years |
| Location | 280 Main St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144328642 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 10349 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Home Health & Hospice Care | Merrimack, NH | Home health agency |
| Southern Nh Medical Center | Nashua, NH | Hospital |
| St Joseph Hospital | Nashua, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foundation Medical Partners Inc | 9436140456 | 280 |
News Archive
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.
Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.
Chlamydia are bacteria that can infect human and animal cells. Human health is particularly affected by Chlamydia pneumoniae (Cpn) and Chlamydia trachomatis.
› Verified 2 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.
Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.
Chlamydia are bacteria that can infect human and animal cells. Human health is particularly affected by Chlamydia pneumoniae (Cpn) and Chlamydia trachomatis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Salvatore Joseph Vella Jr, DO 280 Main St, Second Floor, Nashua, NH 03060-2919 Ph: (603) 577-3300 | Dr Salvatore Joseph Vella Jr, DO 280 Main St, Second Floor, Nashua, NH 03060-2919 Ph: (603) 577-3300 |
News Archive
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
ST Cardio Technologies, an innovative developer of products utilized in the diagnosis and treatment of heart arrhythmias, announced today that it has been awarded a grant of $244,479 under the Qualifying Therapeutic Discovery Project (QTDP) Program. The company's grant is related to the development and clinical evaluation of the Z6 Cardiac Stimulator. The amount awarded to ST Cardio Technologies represents the maximum award for a grant under this program.
Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.
Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.
Chlamydia are bacteria that can infect human and animal cells. Human health is particularly affected by Chlamydia pneumoniae (Cpn) and Chlamydia trachomatis.
› Verified 2 days ago
Christopher Michael Riccio, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-594-6337 Fax: 603-594-6330 | |
Dr. Mark Liebling, Internal Medicine Medicare: Medicare Enrolled Practice Location: 166 Kinsley St Ste 301, Nashua, NH 03060 Phone: 603-883-5673 Fax: 603-689-1343 | |
Dr. Chengta Richard Dai, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 168 Kinsley Street, Suite 20, Nashua, NH 03060 Phone: 603-578-9363 Fax: 603-578-9539 | |
Dr. William Stephan, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 168 Kinsley St, Nashua, NH 03060 Phone: 603-889-4131 | |
Ihab M Ziada, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 173 Daniel Webster Hwy, Nashua, NH 03060 Phone: 603-891-4500 | |
Ajay K Sharma, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2039 Fax: 603-882-5656 | |
Dr. Gianfranco Tulliano, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2045 Fax: 603-577-5644 |